Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDA-DEP: Accelerated iTBS With D-cycloserine Augmentation for Depression
2025-521686-27-01Phase 2Authorised
- Sponsor
- Region Uppsala
- Start
- Sep 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing D-cycloserine augmentation with Placebo augmentation (2 arms). Primary endpoint: Change in MADRS total score from baseline to Day 28. Planned start Sep 2025; status: authorised.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-521686-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521686-27-01.